Literature DB >> 3033325

Two strains of Epstein-Barr virus (B95-8 and a P3HR-1 subclone) that lack defective genomes induce early antigen and cause abortive infection of Raji cells.

J C Lin, N Raab-Traub.   

Abstract

The heterogeneity of Epstein-Barr virus (EBV) obtained from P3HR-1 cells has permitted derivation of a distinct subclone of P3HR-1 (L. Heston, M. Rabson, N. Brown, and G. Miller, Nature (London) 295:160-163, 1982). We have analyzed the biologic properties and genomic structure of this subclonal virus (clone 13) compared with those of parental P3HR-1 and B95-8 viruses. Synthesis of EBV compared with those of parental P3HR-1 and B95-8 viruses. Synthesis of EBV proteins in Raji cells superinfected with virus derived from P3HR-1, clone 13, and B95-8 was analyzed both by fluorography of radiolabeled proteins and by immunoblotting. Highly concentrated preparations of clone 13 and B95-8 virus induced most of the spectrum of EBV proteins in Raji cells with the exception of the 145,000-, 140,000-, and 110,000-molecular-weight proteins, which were either undetectable or reduced. Moreover, both clone 13 and B95-8 viruses also induced the same patterns of early antigen diffuse components as the parental P3HR-1 virus did. However, only P3HR-1 virus could induce EBV DNA synthesis in superinfected Raji cells, as determined both by buoyant density centrifugation and by in situ cytohybridization with biotinylated recombinant EBV DNA probes. Defective heterogeneous molecules present in P3HR-1 virus have been implicated in early antigen induction after superinfection of Raji cells. Therefore, Southern blots of clone 13, P3HR-1, and B95-8 viruses were hybridized to recombinant EBV fragments representing the sequences contained within the defective molecules in P3HR-1. The parental P3HR-1 contained the previously described defective molecules. No evidence for defective molecules was found in clone 13 or B95-8 viruses. These data indicate that concentrated preparations of both clone 13 and B95-8 viruses can induce abortive infection in Raji cells, but while the defective molecules are not needed for induction of early antigen diffuse components, they may be required for the induction of viral DNA synthesis.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3033325      PMCID: PMC254207          DOI: 10.1128/JVI.61.6.1985-1991.1987

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  28 in total

1.  Activation of expression of latent Epstein-Barr herpesvirus after gene transfer with a small cloned subfragment of heterogeneous viral DNA.

Authors:  J Countryman; G Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1985-06       Impact factor: 11.205

2.  Qualitative and quantitative analyses of Epstein-Barr virus early antigen diffuse component by western blotting enzyme-linked immunosorbent assay with a monoclonal antibody.

Authors:  J C Lin; E I Choi; J S Pagano
Journal:  J Virol       Date:  1985-03       Impact factor: 5.103

3.  Nucleotide sequence and predicted amino acid sequence of a protein encoded in a small herpes simplex virus DNA fragment capable of trans-inducing alpha genes.

Authors:  P E Pellett; J L McKnight; F J Jenkins; B Roizman
Journal:  Proc Natl Acad Sci U S A       Date:  1985-09       Impact factor: 11.205

4.  Sequential detection of different antigens induced by Epstein-Barr virus and herpes simplex virus in the same Western blot by using dual antibody probes.

Authors:  J C Lin; J S Pagano
Journal:  J Virol       Date:  1986-08       Impact factor: 5.103

5.  Identification of herpes simplex virus DNA sequences which encode a trans-acting polypeptide responsible for stimulation of immediate early transcription.

Authors:  M E Campbell; J W Palfreyman; C M Preston
Journal:  J Mol Biol       Date:  1984-11-25       Impact factor: 5.469

6.  Identification of polypeptide components of the Epstein-Barr virus early antigen complex with monoclonal antibodies.

Authors:  G R Pearson; B Vroman; B Chase; T Sculley; M Hummel; E Kieff
Journal:  J Virol       Date:  1983-07       Impact factor: 5.103

7.  P3HR-1 Epstein-Barr virus with heterogeneous DNA is an independent replicon maintained by cell-to-cell spread.

Authors:  G Miller; L Heston; J Countryman
Journal:  J Virol       Date:  1985-04       Impact factor: 5.103

8.  Structure of defective DNA molecules in Epstein-Barr virus preparations from P3HR-1 cells.

Authors:  M S Cho; G W Bornkamm; H zur Hausen
Journal:  J Virol       Date:  1984-07       Impact factor: 5.103

9.  Prolonged inhibitory effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine against replication of Epstein-Barr virus.

Authors:  J C Lin; M C Smith; J S Pagano
Journal:  J Virol       Date:  1984-04       Impact factor: 5.103

10.  Identification of a rare Epstein-Barr virus variant that enhances early antigen expression in Raji cells.

Authors:  M Rabson; L Heston; G Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1983-05       Impact factor: 11.205

View more
  8 in total

1.  Coinfection with multiple strains of the Epstein-Barr virus in human immunodeficiency virus-associated hairy leukoplakia.

Authors:  D M Walling; S N Edmiston; J W Sixbey; M Abdel-Hamid; L Resnick; N Raab-Traub
Journal:  Proc Natl Acad Sci U S A       Date:  1992-07-15       Impact factor: 11.205

2.  Amplification of Epstein-Barr virus (EBV) DNA by superinfection with a strain of EBV derived from nasopharyngeal carcinoma.

Authors:  H Sato; T Takimoto; J S Pagano; N Raab-Traub
Journal:  J Virol       Date:  1988-09       Impact factor: 5.103

3.  Genome rearrangements activate the Epstein-Barr virus gene whose product disrupts latency.

Authors:  C Rooney; N Taylor; J Countryman; H Jenson; J Kolman; G Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

4.  Pan-viral-microRNA screening identifies interferon inhibition as a common function of diverse viruses.

Authors:  Jennifer E Cox; Lydia V McClure; Andrei Goga; Christopher S Sullivan
Journal:  Proc Natl Acad Sci U S A       Date:  2015-01-26       Impact factor: 11.205

5.  Inhibition of Epstein-Barr virus (EBV) release from P3HR-1 and B95-8 cell lines by monoclonal antibodies to EBV membrane antigen gp350/220.

Authors:  T Sairenji; G Bertoni; M M Medveczky; P G Medveczky; Q V Nguyen; R E Humphreys
Journal:  J Virol       Date:  1988-08       Impact factor: 5.103

6.  Biomolecular analysis of a defective nontransforming Epstein-Barr virus (EBV) from a patient with chronic active EBV infection.

Authors:  C Alfieri; J H Joncas
Journal:  J Virol       Date:  1987-10       Impact factor: 5.103

7.  Comparison of two bromovinyl nucleoside analogs, 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil and E-5-(2-bromovinyl)-2'-deoxyuridine, with acyclovir in inhibition of Epstein-Barr virus replication.

Authors:  J C Lin; H Machida
Journal:  Antimicrob Agents Chemother       Date:  1988-07       Impact factor: 5.191

8.  A Temporal Proteomic Map of Epstein-Barr Virus Lytic Replication in B Cells.

Authors:  Ina Ersing; Luis Nobre; Liang Wei Wang; Lior Soday; Yijie Ma; Joao A Paulo; Yohei Narita; Camille W Ashbaugh; Chang Jiang; Nicholas E Grayson; Elliott Kieff; Steven P Gygi; Michael P Weekes; Benjamin E Gewurz
Journal:  Cell Rep       Date:  2017-05-16       Impact factor: 9.423

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.